Sign In
Buy ALNY
$216.98
-2.22 (-1.01%)
At Close: Aug 10, 2026
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
08:00am, Wednesday, 28'th May 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman S
3 High-Flying Stocks That Could Soar Even More
06:40am, Saturday, 24'th May 2025
Many investors love the "big mo." That's short for "big momentum.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
10:00am, Monday, 05'th May 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Secu
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
11:55am, Friday, 02'nd May 2025
ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
01:11pm, Thursday, 01'st May 2025
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenst
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
11:35am, Thursday, 01'st May 2025
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare t
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
10:20am, Thursday, 01'st May 2025
Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.16 per share a year ago.
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:21am, Tuesday, 29'th Apr 2025
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
08:00am, Monday, 28'th Apr 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline
11:09am, Thursday, 24'th Apr 2025
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
08:00am, Thursday, 17'th Apr 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter endi
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?
10:35am, Thursday, 10'th Apr 2025
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
08:00am, Tuesday, 01'st Apr 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 2
